FDA Bolsters Post-Market Scrutiny Of Drugs

Law360, New York (April 23, 2012, 5:20 PM EDT) -- The U.S. Food and Drug Administration has beefed up its scrutiny of drugs after they are initially approved, including issuing more advisories on drug safety issues, as well as requiring more post-market drug studies and new safety labeling, the agency said Saturday.

The agency’s Center for Drug Evaluation and Research said in a report that the FDA had issued 68 drug safety communications — which notify the public about potential drug safety issues — in 2011, up from 39 in 2010. The agency has also required...
To view the full article, register now.